<DOC>
	<DOCNO>NCT01163318</DOCNO>
	<brief_summary>The purpose study collect data incidence adverse drug reaction , infection malignant tumor , well factor might affect safety effectiveness Humira® ( adalimumab ; 40mg/0.8 mL ) Japanese participant receive drug treatment rheumatoid arthritis .</brief_summary>
	<brief_title>Special Investigation Humira® ( Adalimumab ) Long-term Treatment Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Rheumatoid arthritis chronic autoimmune disease require long-term treatment . Due need long-term safety data Japanese participant fulfil condition approval adalimumab Japanese regulatory authority , post-marketing observational study ( PMOS ) conduct . The study investigate long-term safety adalimumab , particularly associate development infection malignant tumor . Data collect every 6 month 3 year .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion criterion : 1 . Participants receive adalimumab accordance indication treatment dosage regimen . 2 . Participants use adalimumab continuously . 3 . Participants without current past history malignant tumor . 4 . Participants evaluate Disease Activity Score 28 4 Erythrocyte Sedimentation Rate ( DAS284ESR ) . 5 . Participants evaluate Health Assessment Questionnaire ( HAQ ) Modified Health Assessment Questionnaire ( MHAQ ) prior initiation adalimumab treatment allcase PMOS . Exclusion criterion : 1 . Contraindications accord package insert . 2 . Participants serious infection . 3 . Participants tuberculosis . 4 . Participants history hypersensitivity ingredient adalimumab . 5 . Participants demyelinate disease history demyelinate disease . 6 . Participants congestive cardiac failure .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>